Direct Answer
Clinical trial technology firms provide software for running drug studies, including electronic data capture, patient recruitment, randomization and decentralized trial tools. They sell subscriptions and services to pharma sponsors and research organizations.
Industry Overview
Clinical Trial Technology sits within the health care sector. The first numbers to compare across companies here are recurring revenue and net retention, number of active studies and backlog. The outside forces that move them are listed under Primary Macro Drivers.
Key Industry Metrics
- Recurring revenue and net retention: Subscription income and how much of last year's customer revenue remains, including upsells. A net retention figure above 100% means existing sponsors are spending more; below it signals churn and shrinking studies.
- Number of active studies: Count of clinical studies currently running on the platform. Each study generates fees through its duration, so growth signals adoption, but study size and phase affect how much each one is worth.
- Backlog: Contracted revenue not yet recognized as studies progress. It gives visibility into future sales, but cancelled or delayed studies can shrink it, so check how much is expected within a year.
- Gross margin: Share of revenue remaining after hosting, support and implementation costs. Software-heavy mixes carry higher margins, while services-heavy work for study setup pulls the figure down.
- Customer concentration among large sponsors: Share of revenue from the biggest drug sponsors. Large buyers bring stability and volume but also pricing power, and a few cancelled programs can move revenue noticeably.
Primary Macro Drivers
- Sponsor research and development spending: Sponsors buy trial software out of research budgets, so more studies being run lifts active studies and recurring revenue, while cuts reduce new contracts.
- Move to decentralized and hybrid trials: Remote visits and home data collection need new software, which lifts sales of recruitment and monitoring tools and can raise the number of studies per customer.
- Regulatory acceptance of digital endpoints: When regulators accept data from wearables and apps as valid evidence, sponsors can use more digital tools, widening what vendors can sell per study.
- Biotech funding: Small drug developers start and fund fewer trials when investors pull back, which slows new study starts and shows up in backlog and bookings.
Major Risks
- Biotech funding downturns: When funding dries up, small sponsors pause or end programs, so new study starts slow and backlog shrinks; watch bookings and the share of revenue from small sponsors.
- Study cancellations: A canceled study stops the subscription and service fees tied to it; watch the cancellation rate and the gap between backlog and recognized revenue.
- Competition from large research organizations: Large research organizations can bundle software with their own services at low cost, pressuring pricing and retention; watch net revenue retention and win rates.
- Data privacy and validation requirements: Systems must follow data protection and validation rules, so a failure or new requirement can raise cost or delay deals; watch compliance disclosures and audit findings.
Industry Characteristics
| Characteristic | Profile |
|---|---|
| Cyclicality | Mixed |
| Capital Intensity | Low |
| Regulatory Intensity | Medium |
| Industry Maturity | Growth |
| Geographic Importance | U.S. / Global |
Companies Associated with Clinical Trial Technology
The SEC's Standard Industrial Classification has no code that describes clinical trial technology as a group, so there is no complete list of its filers. The companies below come from Swoopr's SEC dataset and have operations in or next to the industry. Each is classified by the SEC under its own main business.
| Company | SEC classification | Revenue | Growth | Net margin | Year |
|---|---|---|---|---|---|
| Iqvia Holdings Inc. | Services-Commercial Physical & Biological Research | $16.3 billion | 5.9% | 8.3% | FY 2025 |
| Veeva Systems Inc | Services-Prepackaged Software | $3.2 billion | 16.3% | 28.4% | FY 2026 |
Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. Listing here describes a business relationship to the industry, not a recommendation. To find more companies, use the company directory and the health care hub.
Where to Go Next
The Clinical Trial Technology guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company.
More in Health Care
- Health Care sector overview
- Clinical Workflow Software
- Clinical-Stage Biotechnology
- CNS Pharmaceuticals
- Cell Therapy
- Contract Development & Manufacturing Organizations
- Care Delivery
- Contract Research Organizations
- Cardiovascular Devices
Put it to work
Frequently Asked Questions
What are the main KPIs for the Clinical Trial Technology industry?
Key performance indicators for the Clinical Trial Technology industry include: Recurring revenue and net retention, Number of active studies, Backlog, Gross margin, Customer concentration among large sponsors. Which matter most depends on the company's model, so compare them across several companies rather than relying on one.
How cyclical is the Clinical Trial Technology industry?
The Clinical Trial Technology industry exhibits mixed cyclicality characteristics. Some segments move with the broader economy while others maintain more stable demand, making stock selection within the group particularly important.
What are the biggest risks in the Clinical Trial Technology industry?
The primary risks for Clinical Trial Technology companies include: Biotech funding downturns, Study cancellations, Competition from large research organizations, Data privacy and validation requirements. Investors should assess each company's exposure to these factors and its track record of navigating them.